Cargando…

Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis

Leishmaniasis is a neglected tropical disease affecting more than 12 million people worldwide, which in its visceral clinical form (VL) is characterised by the accumulation of parasites in the liver and spleen, and can lead to death if not treated. Available treatments are not well tolerated due to...

Descripción completa

Detalles Bibliográficos
Autores principales: Bezerra-Souza, Adriana, Fernandez-Garcia, Raquel, Rodrigues, Gabriela F., Bolas-Fernandez, Francisco, Dalastra Laurenti, Marcia, Passero, Luiz Felipe, Lalatsa, Aikaterini, Serrano, Dolores R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680852/
https://www.ncbi.nlm.nih.gov/pubmed/31330776
http://dx.doi.org/10.3390/pharmaceutics11070353
_version_ 1783441596560179200
author Bezerra-Souza, Adriana
Fernandez-Garcia, Raquel
Rodrigues, Gabriela F.
Bolas-Fernandez, Francisco
Dalastra Laurenti, Marcia
Passero, Luiz Felipe
Lalatsa, Aikaterini
Serrano, Dolores R.
author_facet Bezerra-Souza, Adriana
Fernandez-Garcia, Raquel
Rodrigues, Gabriela F.
Bolas-Fernandez, Francisco
Dalastra Laurenti, Marcia
Passero, Luiz Felipe
Lalatsa, Aikaterini
Serrano, Dolores R.
author_sort Bezerra-Souza, Adriana
collection PubMed
description Leishmaniasis is a neglected tropical disease affecting more than 12 million people worldwide, which in its visceral clinical form (VL) is characterised by the accumulation of parasites in the liver and spleen, and can lead to death if not treated. Available treatments are not well tolerated due to severe adverse effects, need for parenteral administration and patient hospitalisation, and long duration of expensive treatments. These treatment realities justify the search for new effective drugs, repurposing existing licensed drugs towards safer and non-invasive cost-effective medicines for VL. In this work, we provide proof of concept studies of butenafine and butenafine self-nanoemulsifying drug delivery systems (B-SNEDDS) against Leishmania infantum. Liquid B-SNEDDS were optimised using design of experiments, and then were spray-dried onto porous colloidal silica carriers to produce solid-B-SNEDDS with enhanced flow properties and drug stability. Optimal liquid B-SNEDDS consisted of Butenafine:Capryol 90:Peceol:Labrasol (3:49.5:24.2:23.3 w/w), which were then sprayed-dried with Aerosil 200 with a final 1:2 (Aerosil:liquid B-SNEDDS w/w) ratio. Spray-dried particles exhibited near-maximal drug loading, while maintaining excellent powder flow properties (angle of repose <10°) and sustained release in acidic gastrointestinal media. Solid-B-SNEDDS demonstrated greater selectivity index against promastigotes and L. infantum-infected amastigotes than butenafine alone. Developed oral solid nanomedicines enable the non-invasive and safe administration of butenafine as a cost-effective and readily scalable repurposed medicine for VL.
format Online
Article
Text
id pubmed-6680852
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66808522019-08-09 Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis Bezerra-Souza, Adriana Fernandez-Garcia, Raquel Rodrigues, Gabriela F. Bolas-Fernandez, Francisco Dalastra Laurenti, Marcia Passero, Luiz Felipe Lalatsa, Aikaterini Serrano, Dolores R. Pharmaceutics Article Leishmaniasis is a neglected tropical disease affecting more than 12 million people worldwide, which in its visceral clinical form (VL) is characterised by the accumulation of parasites in the liver and spleen, and can lead to death if not treated. Available treatments are not well tolerated due to severe adverse effects, need for parenteral administration and patient hospitalisation, and long duration of expensive treatments. These treatment realities justify the search for new effective drugs, repurposing existing licensed drugs towards safer and non-invasive cost-effective medicines for VL. In this work, we provide proof of concept studies of butenafine and butenafine self-nanoemulsifying drug delivery systems (B-SNEDDS) against Leishmania infantum. Liquid B-SNEDDS were optimised using design of experiments, and then were spray-dried onto porous colloidal silica carriers to produce solid-B-SNEDDS with enhanced flow properties and drug stability. Optimal liquid B-SNEDDS consisted of Butenafine:Capryol 90:Peceol:Labrasol (3:49.5:24.2:23.3 w/w), which were then sprayed-dried with Aerosil 200 with a final 1:2 (Aerosil:liquid B-SNEDDS w/w) ratio. Spray-dried particles exhibited near-maximal drug loading, while maintaining excellent powder flow properties (angle of repose <10°) and sustained release in acidic gastrointestinal media. Solid-B-SNEDDS demonstrated greater selectivity index against promastigotes and L. infantum-infected amastigotes than butenafine alone. Developed oral solid nanomedicines enable the non-invasive and safe administration of butenafine as a cost-effective and readily scalable repurposed medicine for VL. MDPI 2019-07-20 /pmc/articles/PMC6680852/ /pubmed/31330776 http://dx.doi.org/10.3390/pharmaceutics11070353 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bezerra-Souza, Adriana
Fernandez-Garcia, Raquel
Rodrigues, Gabriela F.
Bolas-Fernandez, Francisco
Dalastra Laurenti, Marcia
Passero, Luiz Felipe
Lalatsa, Aikaterini
Serrano, Dolores R.
Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis
title Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis
title_full Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis
title_fullStr Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis
title_full_unstemmed Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis
title_short Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis
title_sort repurposing butenafine as an oral nanomedicine for visceral leishmaniasis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680852/
https://www.ncbi.nlm.nih.gov/pubmed/31330776
http://dx.doi.org/10.3390/pharmaceutics11070353
work_keys_str_mv AT bezerrasouzaadriana repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis
AT fernandezgarciaraquel repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis
AT rodriguesgabrielaf repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis
AT bolasfernandezfrancisco repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis
AT dalastralaurentimarcia repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis
AT passeroluizfelipe repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis
AT lalatsaaikaterini repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis
AT serranodoloresr repurposingbutenafineasanoralnanomedicineforvisceralleishmaniasis